Back to top
more

PetMed Express (PETS)

(Delayed Data from NSDQ)

$3.90 USD

3.90
97,084

+0.04 (1.04%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $3.90 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 250)

Industry: Internet - Commerce

Better trading starts here.

Zacks News

Surmodics (SRDX) Beats on Earnings in Q1, Guidance Solid

Solid performance in the In Vitro Diagnostics segment drives Surmodics (SRDX) in first-quarter fiscal 2018.

    Expedia (EXPE) Q4 Earnings Miss Estimates, Revenues Up Y/Y

    Expedia's (EXPE) fourth-quarter results hurt by continuing investments in accelerated supply acquisition and cloud migration.

      CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat

      A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.

        Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View

        Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.

          Nielsen (NLSN) Q4 Earnings Up Y/Y, Revenues Match Estimates

          Nielsen (NLSN) delivers strong fourth-quarter profits driven by strength in Watch segment. Weakness in the U.S. Buy segment continues to be a concern.

            Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Lag

            Cardiovascular Systems (CSII) witnesses year-over-year increase in Q2 revenues on strength in both the segments.

              STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up

              STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.

                The Zacks Analyst Blog Highlights: Capital City Bank, HCA, MSCI, PetMed and Saia

                The Zacks Analyst Blog Highlights: Capital City Bank, HCA, MSCI, PetMed and Saia

                  Cerner (CERN) Misses Q4 Earnings Estimates, Bookings Soar

                  Despite a decline in earnings year over year, all-time high bookings drive Cerner's (CERN) top line in Q4.

                    Tirthankar Chakraborty headshot

                    5 Top Stocks to Buy During This Bull & Bear Tug-of-War

                    While bullish investors show optimism on corporate earnings and prospects of tax cut, those with a bearish view fear that the Fed's embarking on a quicker route to interest rate hikes might derail the record bull run.

                      Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up

                      Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.

                        Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2

                        Myriad Genetics' (MYGN) year over year decline in revenue was in Q2 is disappointing. However, strong demand for GeneSight tests was encouraging.

                          PetMed Express, Beazer Homes, Taylor Morrison, iRobot and NVIDIA as Zacks Bull and Bear of the Day

                          PetMed Express, Beazer Homes, Taylor Morrison, iRobot and NVIDIA as Zacks Bull and Bear of the Day

                            Brian Bolan headshot

                            Top Stock Picks for the Week of February 5th

                            Two Stocks That Have Attractive Qualities for Investors.

                              LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising

                              LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.

                                AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up

                                Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.

                                  Phibro Animal (PAHC) Beats on Q2 Earnings, Raises Guidance

                                  Phibro (PAHC) witnesses year-over-year improvement across all segments in Q2.

                                    Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid

                                    Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.

                                      Top Ranked Growth Stocks to Buy for February 6th

                                      Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 6th:

                                        Brian Bolan headshot

                                        Bull Of The Day PetMed Express (PETS)

                                        A solid earnings report and a lawsuit dismissal could make the shorts turn tail on this stock.

                                          athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4

                                          Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.

                                            Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4

                                            Omnicell's (OMCL) year-over-year growth at both the segments in Q4 is encouraging.

                                              ABIOMED (ABMD) Beats Earnings and Revenue Estimates in Q3

                                              ABIOMED (ABMD) rides high on record revenues from Impella in third-quarter fiscal 2018. The company is also well poised with new accomplishments.

                                                Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up

                                                Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.

                                                  Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues

                                                  Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.